.Attribute Medicine, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA research study, after a median follow-up of 11 months, patients with metastatic gastrointestinal growths who acquired biomarker-matched treatments based on distributing tumor DNA profiling revealed a better scientific perk than those acquiring unequaled treatment.